Virtus Therapeutics Corporation

Virtus Therapeutics CorporationVirtus Therapeutics CorporationVirtus Therapeutics Corporation

Virtus Therapeutics Corporation

Virtus Therapeutics CorporationVirtus Therapeutics CorporationVirtus Therapeutics Corporation
  • Home
  • About
  • Research & Development
  • Contact
  • More
    • Home
    • About
    • Research & Development
    • Contact

  • Home
  • About
  • Research & Development
  • Contact

New therapies for neurodegenerative diseases

New therapies for neurodegenerative diseases New therapies for neurodegenerative diseases New therapies for neurodegenerative diseases
Contact Us

New therapies for neurodegenerative diseases

New therapies for neurodegenerative diseases New therapies for neurodegenerative diseases New therapies for neurodegenerative diseases
Contact Us

About Us

Our Technology

Virtus' first disease target is PKAN (Pantothenate Kinase-Associated Neurodegeneration). We use biochemical, cell biological, structural, genomic, transcriptomic, metabolomic and proteomic data to guide our strategy to develop the most effective therapy for treatment of this genetic disorder.

Subscribe

Sign up to hear from us.

Leadership

Founder

Choukri Ben Mamoun, PhD

John F. Enders Professor of Medicine (Infectious Diseases), Microbial Pathogenesis and Pathology.


Yale School of Medicine

 

Learn more

Reviews

Contact Us

Please send us a message or call us for an appointment. 


Virtus Therapeutics

virtusadm@virtustherapeutics.com

Hours

Monday - Friday: 8:00am - 5:00pm

Saturday - Sunday: Closed

Copyright © 2026 Virtus Therapeutics - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept